Studies have demonstrated that the cAMP, which acts as a second signaling molecule, can inhibit the progression of glioma [65], and decreased expression of GNAL may be the main reason for the dysregulation of this pathway in glioma. This evidence concerns the gene GNAL and central nervous system cancer.